BACKGROUND: The diagnosis of uterine sarcoma is associated with poor outcome for the patient and there is a need for reliable prognostic markers. Most previous studies on the prognostic value of DNA ploidy include few uterine sarcomas and report conflicting results. MATERIALS AND METHODS: We examined the prognostic value of DNA ploidy and its association with clinicopathological parameters and crude survival in a total population of 354 sarcoma. RESULTS: In univariate analyses, we observed significantly better crude survival for endometrial stromal sarcomas (ESS) and adenosarcoma (AS) patients with diploid as compared with nondiploid tumors, but not for patients with leiomyosarcomas (LMS). In Cox multivariate analyses, DNA ploidy was the only significant predictor of survival for patients with AS. In LMS, mitotic index (MI), tumor size, tumor extent and tumor margins, whereas for ESS, MI, tumor extent and tumor necrosis obtained independent significance of survival. DNA ploidy was a significant predictor of survival for LMS patients in Cox regression analyses when excluding MI. CONCLUSION: DNA ploidy might be useful as a prognostic marker in patients with LMS and AS.
BACKGROUND: The diagnosis of uterine sarcoma is associated with poor outcome for the patient and there is a need for reliable prognostic markers. Most previous studies on the prognostic value of DNA ploidy include few uterine sarcomas and report conflicting results. MATERIALS AND METHODS: We examined the prognostic value of DNA ploidy and its association with clinicopathological parameters and crude survival in a total population of 354 sarcoma. RESULTS: In univariate analyses, we observed significantly better crude survival for endometrial stromal sarcomas (ESS) and adenosarcoma (AS) patients with diploid as compared with nondiploid tumors, but not for patients with leiomyosarcomas (LMS). In Cox multivariate analyses, DNA ploidy was the only significant predictor of survival for patients with AS. In LMS, mitotic index (MI), tumor size, tumor extent and tumor margins, whereas for ESS, MI, tumor extent and tumor necrosis obtained independent significance of survival. DNA ploidy was a significant predictor of survival for LMSpatients in Cox regression analyses when excluding MI. CONCLUSION: DNA ploidy might be useful as a prognostic marker in patients with LMS and AS.
Authors: Birgitte Nielsen; Andreas Kleppe; Tarjei Sveinsgjerd Hveem; Manohar Pradhan; Rolf Anders Syvertsen; John Arne Nesheim; Gunnar Balle Kristensen; Jone Trovik; David James Kerr; Fritz Albregtsen; Håvard Emil Danielsen Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Birgitte Nielsen; Tarjei Sveinsgjerd Hveem; Wanja Kildal; Vera M Abeler; Gunnar B Kristensen; Fritz Albregtsen; Håvard E Danielsen Journal: Cytometry A Date: 2014-12-05 Impact factor: 4.355
Authors: Kim M Boerkamp; Gerard R Rutteman; Marja J L Kik; Jolle Kirpensteijn; Christoph Schulze; Guy C M Grinwis Journal: Cancers (Basel) Date: 2012-12-03 Impact factor: 6.639